NCT04224636View on ClinicalTrials.gov

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
COMBINATION_PRODUCT

Atezolizumab Injection, Bevacizumab Injection

Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE

Trial Locations (7)

50931

RECRUITING

University Hospital Cologne, Cologne

72076

RECRUITING

University Hospital Tübingen, Tübingen

81377

RECRUITING

Hospital of the University of Munich, Munich

81675

RECRUITING

Klinikum Rechts der Isar of the Technical University Munich, Munich

93053

RECRUITING

University Hospital Regensburg, Regensburg

Unknown

RECRUITING

University of Bonn, Bonn

RECRUITING

Würzburg University Hospital, Würzburg

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER